Pharmanest AB

The Challenge

Experiences of pain in connection with gynecological procedures and in childbirth are well documented. It is also well known that the range of effective treatments for local pain relief in gynecology and obstetrics is very limited.

Millions of women undergo gynecological procedures with no or insufficient pain relief.

Pharmanest’s Solution

Pharmanest is developing unique new formulations based on well documented active substances. The formulations are applied topically in the cervix and uterus using applicators developed in-house. Pain relief is obtained immediately, no advanced instrumentation is required and the systemic effect is minimized.

Competitive advantages

Pharmanest’s first product candidate SHACT has been developed for use in local pain relief in connection with the insertion of IUDs. There are few local pain relief products with documented efficacy on the market at present, and the patient therefore has no choice but oral products or no pain relief at all.

With its candidate products, Pharmanest hopes to be able to offer effective local pain relief which is advantageous from both the patient and health economics perspectives.

The Market

Some 150 million women around the world have an IUD1. The medical need for local pain relief when the IUD is inserted has been confirmed by recently conducted market surveys2. Around two-thirds of women with experience of IUDs who were interviewed would choose this type of product if it was available.

Pharmanest’s product candidates also offer potential in other indications such as pain relief in connection with hysteroscopy, abortions and obstetric pain.